HOME >> BIOLOGY >> NEWS
New standard for voice saving care of larynx cancer patients

Results of a national clinical trial confirm that simultaneous treatment with chemotherapy and radiation preserves the voice of patients with advanced larynx cancer without compromising survival rates. The findings, reported in the November 27, 2003 issue of the New England Journal of Medicine are compelling enough to have the combination treatment become the standard of care for such patients, the study's authors report.

"Chemotherapy and radiation together are recommended for advanced laryngeal cancer patients who are otherwise in good health and want to preserve their voice," says Arlene Forastiere, M.D., professor of oncology and otolaryngology at the Johns Hopkins Kimmel Cancer Center and chair of the study. "For patients who have other significant medical problems or little support at home, we would recommend radiation alone. In all cases, patients should be followed closely during treatment by a head and neck surgeon, so that surgery can be performed if there is residual or recurrent cancer after treatment." This year, approximately 9,500 Americans will be diagnosed with laryngeal cancer and 3,800 will die from the disease.

Experience with combined treatment, Forastiere adds, has reduced the need for complete removal of the larynx from 100 percent to about 15 percent. Removing the larynx leaves patients unable to speak with their natural voice and typically use speaking aids such as an electronic device. Other previously-studied treatment options included radiation therapy alone or several cycles of chemotherapy followed by radiation. Studies from a decade ago showed that the survival rate of patients treated with chemotherapy followed by radiation was just as good as those receiving surgery.

This new study of 547 patients shows that giving chemotherapy and radiation together instead of sequentially is more effective in preserving the voice box. 88 percent of patients receiving chemotherapy and radiation together still had their voice
'"/>

Contact: Vanessa Wasta
wastava@jhmi.edu
410-955-1287
Johns Hopkins Medical Institutions
26-Nov-2003


Page: 1 2

Related biology news :

1. Somethings fishy about new NIST food standard
2. First ever standards linking climate change, biodiversity and poverty seek global peer review
3. When combining new oral anti-cancer agents with standard chemotherapy, timing may be crucial
4. New standard to help diagnose heart attacks
5. New standard on the menu, certified slurried spinach
6. Use of new direct thrombin inhibitor may be as effective as current standard treatment
7. Nationwide organic standards to be launched Monday
8. Evidence suggests that standard smallpox vaccine offers long-term immunity
9. Radiation alone after surgery still the standard for head and neck cancer
10. New standards from NIST may provide all-natural benefits
11. Ames Laboratory pursues new standard in sensor technology

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New standard for voice saving care larynx cancer patients

(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:11/21/2014)... 18, 2014 According to a ... Systems (Video, RFID, Access Control, Intrusion Detection, Parking Management, ... Government), Component Service Geography - Global Forecasts to 2020", ... projected to be around $25 Billion in 2014 and ... at a CAGR of 8.69%. Browse 116 ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3
(Date:12/17/2014)... 17, 2014 Ipsen Biopharmaceuticals, Inc., ... ADR: IPSEY), today announced that Somatuline® ... Somatuline®) was approved by the U.S. Food and ... neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, ... disease to improve progression-free survival (PFS). , “The ...
(Date:12/17/2014)... 17, 2014 This report is ... Tubing industry. For an overview analysis, the report ... industry chain structure, industry overview, policy analysis, and ... industry has witnessed rapid development with key ... acquisitions. This report mentions quartz tubing upstream raw ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... , Dec. 16, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic disease, today announced the next step in ... premier bio-analytics solutions provider with the naming of current ... and Chief Executive Officer, while current Chairman of the ... to serve as Chairman. These changes are effective January ...
Breaking Biology Technology:Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 82020 Quartz Tubing Market: Global Development & Forecasts Analysis Now at DeepResearchReports.com 2ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4
Cached News: